Vinorelbine: An active, non cross-resistant drug in advanced breast cancer. Results from a phase II study
- 1 October 1996
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 39 (3) , 285-291
- https://doi.org/10.1007/bf01806156
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.Journal of Clinical Oncology, 1994
- Multidrug resistance in cancer chemotherapyInvestigational New Drugs, 1994
- Vinorelbine as first-line chemotherapy for metastatic breast carcinoma.Journal of Clinical Oncology, 1994
- Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy.Journal of Clinical Oncology, 1993
- Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteriaInvestigational New Drugs, 1992
- Survival of patients with metastatic breast cancer diagnosed between 1955 and 1980Journal of Surgical Oncology, 1991
- Navelbine: a new step in cancer therapy?1989
- Safety and tolerance of Navelbine in phase I-II clinical studies.1989
- Phase-II study of Navelbine in advanced breast cancer.1989
- The importance of dose intensity in chemotherapy of metastatic breast cancer.Journal of Clinical Oncology, 1984